Japanese gastric cancer treatment guidelines 2025 (7th edition)
Japanese Gastric Cancer Association · 2026 · Japan
Source and licence
- Authors
- Japanese Gastric Cancer Association
- Title
- Japanese gastric cancer treatment guidelines 2025 (7th edition)
- Journal
- Gastric Cancer, 2026
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC12956939
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
The 7th edition of the Gastric Cancer Treatment Guidelines was published in March 2025 covering new evidences. Following the format of the previous edition, this guideline consists of a text-based “Treatment” section and a “Clinical Questions” section that includes recommendations and explanations for clinical questions. The Treatment section describes the established standard treatments for gastric cancer, including surgery, endoscopic resection, and chemotherapy. The Clinical Questions section is based on a literature search and evaluation by the independent systematic review team. This allows for evidence-based responses to clinical issues and also presents future research topics in gastric cancer treatment.
Contents of the original publication
The section headings of the original.
- Preface to the English version
- Preface to the Japanese gastric cancer treatment guidelines 7th edition
- Treatments
- Treatment modalities and their indications
- Surgery
- Types and definitions of gastric surgery
- Extent of gastric resection
- Lymph node dissection
- Esophagogastric junctional cancer
- Miscellaneous
- Reconstruction after gastrectomy
- Endoscopic resection
- Methods of endoscopic resection
- Handling of endoscopically resected specimens
- Indications for endoscopic resection (CQ17)
- Curability of endoscopic resection
- Management after endoscopic resection (Fig. 7)
- Systemic chemotherapy for unresectable advanced/recurrent gastric cancer (AGC)
- Principles of indications for systemic chemotherapy of AGC
- Definition of the recommendation grade and evidence level for each chemotherapeutic regimen
- First-line treatment for unresectable advanced/recurrent gastric cancer
- Second-line treatment for unresectable advanced/recurrent gastric cancer
- Third- or later-line treatment for unresectable advanced/recurrent gastric cancer
- Adjuvant chemotherapy
- Clinical significance of postoperative adjuvant chemotherapy
- Indications
- Neoadjuvant chemotherapy
- Palliative care
- Clinical pathway after surgery for gastric cancer
- Follow-up surveillance after surgery for gastric cancer
- Clinical questions for surgery (Table 5)
- Clinical questions for the indication of minimally invasive surgery
- Clinical questions for function-preserving surgery
- Clinical questions for combined resection and extended surgery
- Clinical questions for appropriate staging
- Clinical questions for Stage IV gastric cancer
- Clinical questions for esophagogastric junctional cancer
- Clinical questions for carcinoma of the gastric remnant
- Clinical question for reoperation after gastrectomy
- Clinical questions for long-term impairment after gastrectomy
- Clinical questions for elderly patients
- Clinical questions for chemotherapy
- Clinical questions for palliative care
- Clinical questions for perioperative chemotherapy
- Clinical questions for endoscopic resection
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint